Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer.
COX7A2L
aspartate
electron transport chain
hypoxia
pancreatic cancer
respiration
supercomplexes
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
received:
21
05
2020
revised:
19
07
2020
accepted:
15
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
16
9
2021
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive fibrosis and hypovascularization, resulting in significant intratumoral hypoxia (low oxygen) that contributes to its aggressiveness, therapeutic resistance, and high mortality. Despite oxygen being a fundamental requirement for many cellular and metabolic processes, and the severity of hypoxia in PDAC, the impact of oxygen deprivation on PDAC biology is poorly understood. Investigating how PDAC cells survive in the near absence of oxygen, we find that PDAC cell lines grow robustly in oxygen tensions down to 0.1%, maintaining mitochondrial morphology, membrane potential, and the oxidative metabolic activity required for the synthesis of key metabolites for proliferation. Disrupting electron transfer efficiency by targeting mitochondrial respiratory supercomplex assembly specifically affects hypoxic PDAC proliferation, metabolism, and in vivo tumor growth. Collectively, our results identify a mechanism that enables PDAC cells to thrive in severe, oxygen-limited microenvironments.
Identifiants
pubmed: 33027658
pii: S2211-1247(20)31220-1
doi: 10.1016/j.celrep.2020.108231
pmc: PMC7573785
mid: NIHMS1635588
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108231Subventions
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232124
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA117969
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI080192
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157490
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM095567
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA188048
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests A.C.K. has financial interests in Vescor Therapeutics. A.C.K. is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagy control of iron metabolism. A.C.K. is on the Scientific Advisory Board of Rafael/Cornerstone Pharmaceuticals. A.C.K. is a consultant for Deciphera. The other authors declare no competing interests.